GlassScriptPhysician profile
Timothy R Peters
NPI 1376511998
$7,605.69
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $1,672 · 2021: $2,152 · 2022: $1,574.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,098.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $791.09 | 2019-2022 | |
| Pfizer INC. | $648.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $635.74 | 2019-2022 | |
| Abbvie INC. | $489.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $485.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $386.15 | 2019-2022 | |
| Lilly USA, LLC | $325.82 | 2019-2022 | |
| Novo Nordisk INC | $320.75 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $307.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $244.42 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $154.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $149.12 | 2020-2021 | |
| Boston Scientific Corporation | $140.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.58 | 2019-2021 |
Show all 43 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.